Value Sense
JANX
Janux Therapeutics, Inc. (JANX)
Last Price$29.3(3.2%)
Market Cap$1,656.1M
EV/EBIT LTM
(26.0x)
5Y avg
(14.7x)
Biotechnology industry median
(0.5x)
Stock quality & Intrinsic value
6/10
(0.3%) overvalued
JANX
is (32.8%) overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

Janux Therapeutics, Inc. EV/EBIT LTM

Annual
Quarterly
Daily
Crunching data... Almost there!
Dec'21Dec'22Dec'23Dec'24
EV/EBIT LTM
(20.5x)
(3.7x)
(2.4x)
(26.0x)
JANX
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for JANX and see if it's the right time to invest.
Dive in

Janux Therapeutics, Inc. (JANX) EV/EBIT LTM comparison analysis

General

LTM EV/EBIT LTM

OTHER METRICS

Company name

Revenue growth

EPS growth

Net Income margin

Janux Therapeutics, Inc. logo
Janux Therapeutics, Inc.JANX
(6.6x)
31.0%
(3.0%)
(651.6%)
Median Peer Set
(0.1x)
14.8%
(19.3%)
7.5%
BioMarin Pharmaceutical Inc. logo
BioMarin Pharmaceutical Inc.BMRN
28.0x
18.0%
139.3%
15.0%
Royalty Pharma plc logo
Royalty Pharma plcRPRX
15.8x
(3.8%)
(43.7%)
37.9%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
15.2x
8.3%
10.4%
31.1%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
7.8x
23.6%
25.7%
41.5%
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
(0.3x)
73.7%
467.1%
(35.9%)
BioNTech SE logo
BioNTech SEBNTX
(4.1x)
(77.4%)
(89.7%)
24.4%
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
(61.2x)
N/A
(68.7%)
N/A
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
(165.7x)
23.0%
(38.6%)
(12.4%)
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
(488.1x)
11.7%
N/A
(4.9%)
argenx SE logo
argenx SEARGX
N/A
198.6%
(60.5%)
(24.1%)

JANX key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24
Revenue
% growth
0.0
0.0%
0.0
0.0%
3.6
0.0%
8.6
136.8%
8.1
(6.1%)
10.6
31.0%
Cost of Goods Sold (COGS)0.00.00.10.82.00.0
Gross Profit
% margin
(0.0)
0.0%
(0.0)
0.0%
3.5
96.9%
7.8
90.2%
6.1
75.8%
10.6
100.0%
Operating Expenses3.84.836.675.781.1109.4
Research & Development Expenses (R&D)3.03.026.253.454.968.4
Selling, General & Administrative Expenses (SG&A)0.81.810.322.326.141.0
Operating Income
% margin
(3.8)
0.0%
(4.8)
0.0%
(32.9)
(905.4%)
(67.1)
(779.0%)
(73.0)
(902.9%)
(98.8)
(933.6%)
Interest Income0.20.20.34.014.729.9
Interest Expense0.20.20.04.00.00.0
Pre-tax Income(4.0)(6.8)(32.7)(63.1)(58.3)(69.0)
Income Tax
% effective tax rate
0.2
(5.8%)
(1.5)
22.5%
(0.1)
0.3%
(8.9)
14.1%
0.0
0.0%
0.0
0.0%
Net Income
% margin
(4.2)
0.0%
(5.3)
0.0%
(32.6)
(895.2%)
(54.2)
(628.8%)
(58.3)
(721.2%)
(69.0)
(651.6%)
EPS(0.10)(0.13)(0.79)(1.31)(1.32)(1.28)
Diluted EPS(0.10)(0.13)(0.79)(1.31)(1.32)(1.28)
EBITDA
% margin
(3.8)
0.0%
(4.8)
0.0%
(32.8)
(902.3%)
(66.3)
(769.3%)
(71.0)
(878.7%)
(98.8)
(933.6%)

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is Janux Therapeutics, Inc.'s EV/EBIT LTM?

As of today, Microsoft Corp's last 12-month EV/EBIT LTM is (26.0x), based on the financial report for Dec 30, 2024 (Q4’2024). The average annual EV/EBIT LTM for Janux Therapeutics, Inc. have been (14.7x) over the past three years, and (11.0x) over the past five years.

2) Is Janux Therapeutics, Inc.'s EV/EBIT LTM Good?

As of today, Janux Therapeutics, Inc.'s EV/EBIT LTM is (26.0x), which is lower than industry median of (0.5x). It indicates that Janux Therapeutics, Inc.'s EV/EBIT LTM is Good.

3) How does Janux Therapeutics, Inc.'s EV/EBIT LTM compare to its peers?

As of today, Janux Therapeutics, Inc.'s EV/EBIT LTM is (26.0x), which is lower than peer median of (0.1x). The list of peers includes BMRN, RPRX, REGN, UTHR, BGNE, BNTX, SMMT, ALNY, VRTX, ARGX.